Pentosidine as a diagnostic marker for chronic Diabetic Nephropathy | ||||
Advances in Environmental and Life Sciences | ||||
Articles in Press, Accepted Manuscript, Available Online from 02 May 2025 | ||||
Document Type: Original research articles | ||||
DOI: 10.21608/aels.2025.328977.1068 | ||||
![]() | ||||
Authors | ||||
Khalid Ibrahim Alghodran ![]() | ||||
1Chemistry Department, Faculty of Science, Suez Canal University, 41522 Ismailia, Egypt | ||||
2Department of Pathology, Faculty of Veterinary Medicine, Suez Canal University, Ismailia 41522, Egypt | ||||
3Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Suez Canal University, Egypt | ||||
Abstract | ||||
ABSTRACT Diabetic nephropathy (DN) is a leading cause of end-stage renal disease, necessitating early assessment of renal function and timely diagnosis of glomerular and tubular injuries in type I and type II diabetic patients. This study aimed to evaluate the validity of pentosidine as an early biomarker for DN. A total of 125 Egyptian subjects from the outpatient clinic at 10th of Ramadan City Health Insurance Hospital, were studied, with 20 healthy controls (Group A) and 105 diabetic patients divided into Group B (diabetes mellitus), Group C (diabetic nephropathy), and Group D (diabetic nephropathy with complications) . Pentosidine levels were significantly elevated in diabetic groups (p < 0.001), with the highest values in Group D. At a cut-off of ≥69.5, pentosidine demonstrated 93.9% sensitivity and 79.7% specificity for diagnosing DN. These findings suggest that pentosidine is a reliable biomarker for assessing DN before the onset of microalbuminuria. Elevated pentosidine levels have been detected as diagnostic marker as well as albuminuria in patients with DN | ||||
Keywords | ||||
Key words: Pentosidine; Diabetic Nephropathy; Biomarker; T2DM | ||||
Statistics Article View: 132 |
||||